The other incretin, GIP, by contrast was somewhat neglected as a therapeutic option, as early research showed an inferior activity of this hormone compared to GLP‐1, even when infused at supraphysiological concentrations8; this is commonly considered to reflect loss of GIP‐sensitivity in patients with type 2 diabetes, possibly as a consequence of chronically elevated plasma glucose.9 This evidence concerns the gene GIP and type 2 diabetes mellitus.